RAC 2.60% $1.58 race oncology ltd

RAC media coverage, page-881

  1. 2,965 Posts.
    lightbulb Created with Sketch. 3584
    The 'official' and only endpoint of the P1b is no dose limiting toxicities. They don't have to report on any ancillary FTO assessment that is being undertaken as part of the biomarker collaboration with Sheba. Not until they have the sufficient commercial protection.

    https://hotcopper.com.au/data/attachments/4199/4199665-800ad46fd9145ac8329226fb0771231e.jpg


    https://hotcopper.com.au/data/attachments/4199/4199686-bf24ba5131f51d4cf1e8fea560c5372a.jpg


 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.